日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis

MET基因拷贝数增加是低分化肺腺癌的一个亚型,预后较差。

Overbeck, Tobias Raphael; Cron, Dana Alina; Schmitz, Katja; Rittmeyer, Achim; Körber, Wolfgang; Hugo, Sara; Schnalke, Juliane; Lukat, Laura; Hugo, Tabea; Hinterthaner, Marc; Reuter-Jessen, Kirsten; Rosenthal, Tessa; Moecks, Joachim; Bleckmann, Annalen; Schildhaus, Hans-Ulrich

ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer

ReadMax——一种用于预测EGFR野生型非小细胞肺癌患者厄洛替尼治疗疗效的新型EGFR基因拷贝数读取和评分方法

Moecks, Joachim; Soulières, Denis; Klughammer, Barbara

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

对接受 EGFR TKI 治疗的 EGFR 突变阳性非小细胞肺癌患者的临床结局进行汇总分析

Paz-Ares, Luis; Soulières, Denis; Moecks, Joachim; Bara, Ilze; Mok, Tony; Klughammer, Barbara

Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14(1-2): 51-69)

回复 Watkins 和 Rukazenkov (J Cell Mol Med 2010),对题为“EGFR 突变 NSCLC 患者的临床结果:汇总分析”的稿件的回复信 (Paz-Ares 等人,J Cell Mol Med. 2010; 14(1-2): 51-69)

Paz-Ares, Luis; Moecks, Joachim; Klughammer, Barbara

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

EGFR突变型非小细胞肺癌患者的临床结局:汇总分析

Paz-Ares, Luis; Soulières, Denis; Melezínek, Ivan; Moecks, Joachim; Keil, Lorenz; Mok, Tony; Rosell, Rafael; Klughammer, Barbara